Home/Filings/4/0001209191-21-071194
4//SEC Filing

Taylor Stacy L 4

Accession 0001209191-21-071194

CIK 0001478320other

Filed

Dec 22, 7:00 PM ET

Accepted

Dec 23, 9:00 PM ET

Size

12.9 KB

Accession

0001209191-21-071194

Insider Transaction Report

Form 4
Period: 2021-12-22
Taylor Stacy L
SVP and General Counsel
Transactions
  • Sale

    Common Stock

    2021-12-22$30.00/sh15,338$460,14015,036 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-12-2210,1305,313 total
    Exercise: $6.55Exp: 2028-04-24Common Stock (10,130 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-12-225,20817,709 total
    Exercise: $7.80Exp: 2029-04-23Common Stock (5,208 underlying)
  • Exercise/Conversion

    Common Stock

    2021-12-22$6.55/sh+10,130$66,35225,166 total
  • Exercise/Conversion

    Common Stock

    2021-12-22$7.80/sh+5,208$40,62230,374 total
Footnotes (3)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021.
  • [F2]The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  • [F3]The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Issuer

Adaptive Biotechnologies Corp

CIK 0001478320

Entity typeother

Related Parties

1
  • filerCIK 0001799081

Filing Metadata

Form type
4
Filed
Dec 22, 7:00 PM ET
Accepted
Dec 23, 9:00 PM ET
Size
12.9 KB